synergychc.com (SNYR): Debt to Book Capitalization Ratio

Corporate company logo of Synergy CHC (SNYR)

High scalability for Synergy CHC Corp (SNYR) is driven by the outsourcing of health product manufacturing. This leverage chart, measuring debt to book capitalization, serves as a confidence indicator, where the level of 0.00 represents the current value. The holding company is expanding R&D in biotech and e-commerce to maintain stable potential, yet it faces rising online promotion costs in its struggle for margins against market behemoths.

SNYR Synergy CHC: Debt to Book Value in the range 10/24/2024 - 10/03/2026
Manufactured products of Synergy CHC

For Synergy CHC Corp (SNYR), this indicator assesses the capital structure stability of the consumer brand holding. The metric compares total liabilities against the book value of equity. By analyzing the history of the debt-to-book capitalization ratio, an investor determines the degree of financial leverage. A decrease in the coefficient minimizes default risk while capitalizing on wellness trends, whereas an increase in the indicator signals aggressive borrowing to scale distribution.

Competing companies

Debts to Book Capitalization HLN (Haleon plc)|Debts to Book Capitalization kenvue.com KVUE|VRNA - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio MENS (Jyong Biotech Limited)|Ligand Pharma (LGND) - Debt to Book Capitalization Ratio|Debt to Book Value Amneal Corp|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com|Debt to Book Value LQDA (Liquidia)|GLPG (Galapagos N.V.) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ANI Pharma ANIP|Afrezza (MNKD) - Debts to Book Value|AMPH: Debt to Book Value|pacira.com - Debt to Book Capital|SPRY: Debts to Book Capitalization|Theravance Biopharma Inc - Debt to Net Assets Ratio|AQST (Aquestive Pharma) - Debts to Book Capitalization|Debts to Book Value scPharma SCPH|Debt to Book Capitalization Ratio Tectonic Therapeutic, Inc. (TECX)|TNXP (tonixpharma.com) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio China SXT Pharmaceuticals, Inc. SXTC|Debts to Net Assets Eupraxia Pharmaceuticals, Inc. (EPRX)|BHST: Debt to Book Value|Debts to Book Value Invizyne|oramed.com (ORMP) - Debt to Book Capitalization Ratio|Debt to Book Value Ratio ENTX|HYFT (MindWalk Holdings Inc.) - Debts to Book Capitalization|Debts to Book Value ABVC BioPharma Inc. ABVC|Debt to Book Capitalization Ratio Cumberland Pharma (CPIX)|QNTM (Quantum BioPharma Corp) - Debt to Net Assets Ratio|Debts to Book Capitalization FGEN (FibroGen, Inc.)|Debt to Net Assets telomirpharma.com|RANI: Debt to Book Value|Debts to Book Value Rallybio Corporation|LEXX (lexariabioscience.com) - Debt to Book Value|Pulmatrix Corporation - Debt to Net Assets Ratio|PTHL (Pheton Holdings Limited) - Debts to Book Capitalization|Debt to Book Value Aptorum (APM)|Debts to Book Capitalization LYRA|IBO (Impact BioMedical, Inc.) - Debt to Net Assets Ratio|Debts to Book Capitalization TNFA (TNF Pharmaceuticals, Inc.)|YCBD - Debt to Book Value|PRFX: Debt to Book Value|Debt to Net Assets Ratio CYTO (Altamira Therapeutics)|LIPO: Debts to Book Capitalization|Debt to Book Value OptiNose Inc|Debt to Book Capitalization Ratio Pieris|Debts to Book Value Procaps Group Corp PROC|Debt to Book Capitalization Ratio Petros Pharmaceuticals (PTPI)|QLI (qlsyy.net) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACELYRIN SLRN|TFFP (TFF Pharmaceuticals Inc.) - Debts to Book Capitalization Ratio